Preliminary studies have also shown the abnormal expression of the immune checkpoint molecule CEACAM1 in T-cells of patients with glioma, which was closely associated with clinical factors, including the pathological grading of tumours, patient functional status, and the level of cytokines [6]. This evidence concerns the gene CEACAM1 and glioma.